Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
2 Blue Chips Under Pressure
07:00am, Sunday, 29'th Jan 2023
Plus, Motley Fool personal finance expert Robert Brokamp answers your questions.
3 Beaten-Down Blue Chip Stocks to Buy Right Now
05:55am, Sunday, 29'th Jan 2023
These solid stocks are down but definitely not out.
The 4% DGI Core Portfolio: 2022 Year-End Review
09:00am, Saturday, 28'th Jan 2023
We present the 2022 year-end review of our eight-year-old Passive DGI-Core Portfolio. We consider this portfolio and strategy as the foundation of our overall portfolio. We will provide updates on cha
Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
01:01am, Friday, 27'th Jan 2023
Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today's market. They offer relatively high yields and at least some value while projec
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
05:33am, Thursday, 26'th Jan 2023
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.
3 Perfect Stocks for Retirees to Buy Hand Over Fist During the Nasdaq Bear Market
05:06am, Thursday, 26'th Jan 2023
These highly profitable, industry-leading companies are ideal for retired investors.
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
04:03am, Thursday, 26'th Jan 2023
The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
Haleon looks good on J&J read across, reckons Credit Suisse
10:06am, Wednesday, 25'th Jan 2023
Haleon, the Glaxo personal care products spin-off, is an increasingly attractive option in the over-the-counter products space, according to Credit Suisse. Results this week from J&J Consumer Health's
Why Johnson & Johnson Stock Was Stagnant Today
06:14pm, Tuesday, 24'th Jan 2023
Investors were on the fence about the company's performance in the final months of last year.
Johnson & Johnson Q4 Earnings Highlight Bullish Path In 2023
05:25pm, Tuesday, 24'th Jan 2023
J&J reported its Q4 results with EPS beating expectations. The company is proving capable of maintaining organic sales growth while supporting margins through cost savings initiatives.
J&J Gets Ready to Break up With Tylenol
01:49pm, Tuesday, 24'th Jan 2023
Johnson & Johnson's consumer business was the only division to deliver growth in the fourth quarter.
Johnson & Johnson's 4Q earnings beat and rosy 2023 outlook fails to distract from slowing sales growth and inflationary pressures
01:37pm, Tuesday, 24'th Jan 2023
Johnson & Johnson (NYSE:JNJ)'s rosy 2023 earnings forecast failed to take the sting off of moderated sales growth and inflationary pressures during the fourth quarter of 2022. For the three-month peri
Johnson & Johnson (JNJ) Q4 2022 Earnings Call Transcript
01:21pm, Tuesday, 24'th Jan 2023
Johnson & Johnson (NYSE:JNJ ) Q4 2022 Results Conference Call January 24, 2023 8:30 AM ET Company Participants Jessica Moore - VP, IR Joaquin Duato - Chairman and CEO Joe Wolk - EVP and CFO Conference
‘Tripledemic' demand for Motrin and Tylenol fueled year-end sales in J&J's consumer business
01:05pm, Tuesday, 24'th Jan 2023
As cases of COVID, flu and respiratory syncytial virus surged in the fall as part of a “tripledemic” in the U.S., demand for cold medications translated to a good quarter for Johnson & Johnson's J
Johnson & Johnson fourth-quarter earnings down 25%
01:00pm, Tuesday, 24'th Jan 2023
The company continues to see pressure on sales from staffing shortages at hospitals, which have limited growth in procedures using J&J products, while inflation has boosted expenses.
